FlexShares High Yield Value-Scored Bond Index Fund Price & Performance (HYGV)

The FlexShares Credit-Scored US Corporate Bond Index Fund, traded as NASDAQ:SKOR, experienced a sharp 76.1% drop in short interest during February. With only 2,600 shares shorted as of mid-February, compared to 10,900 in January, this marks a significant shift in market sentiment toward the fund.1

Analysts at Wedbush forecast BioCryst Pharmaceuticals will achieve positive earnings per share by Q4 2025. With its stock currently trading at $8.47, the company has seen a 40.8% increase in revenue year-over-year. The outlook suggests an upward trajectory in profitability over the next few years.2

Environmental, social, and governance (ESG) ETFs are capturing investor attention with robust returns. Among top performers are BNY Mellon Women's Opportunities ETF, up 43.16% year-to-date, and Franklin Responsibly Sourced Gold ETF, up 41.96%. ESG funds are increasingly viewed as both profitable and impactful investment options.3